Business and Finance

$21.4-billion acquisition realigns research and manufacturing sourcing

Ex-AmerisourceBergen, -Cardinal and -inVentiv Health execs join team

By working with the sales force, incentive plan design can boost a product launch

Will restricting use of rebates in federal programs carry over to commercial insurance?

Senate and House committees begin the legislative process for addressing drug pricing

Annual analysis predicts 3-6% CAGR through 2023, a lower rate than 2014-2018

Even as the science behind the new therapies is getting established, payers are preparing for their extraordinary cost

Spending on drug promotion rose—but not at the rate of pharma sales growth

A deeper commitment to oncology and immunology

Cellular and genetic therapies (CGTs) developers are struggling to build capacity

Oncology represents half of the dollar volume of HDA-member sales

Pfizer’s Ibrance was the star performer from the class of 2015 FDA approvals

Sales volume handled by primary wholesaler/distributors seems to be declining

HFAP builds out from its hospital-accreditation business

Already-built Las Colinas facility will be the global headquarters in April 2019

Most pharmacists want more time to counsel patients; most are concerned with drug reimbursement issues

Billions of dollars are at stake with analyzing and optimizing GTN decisions

PBM squares the circle by offering a lower drug price—where some payers wouldn’t want it

Current McKesson president, Brian Tyler, will take over in April 2019

Biologics, RxCrossroads units will retain their identity

JC Scott takes over as the PBM business undergoes a transformation

Known as the “King of Cold Chain,” Bishara looks both back and ahead at progress in upgrading pharma’s logistics practices

Will the “United States-Mexico Trade Agreement” replace Nafta?

CVS and Express Scripts open more of the curtain around rebates; formulary exclusions grow

HDA issues a report detailing recalls and returns

Alliance for Regenerative Medicine tries to rationalize how payers address economic value

FDA working group’s effort is part of a larger move to realign drug pricing policies

PBMs, wholesalers and insurers lose over $20 billion in stock value on day of announcement

Will a combination of better diagnosis resources and cost cutting lead to better patient outcomes?